...
search icon
atnm-img

Actinium Pharmaceuticals Inc Share Price

ATNM
ASQ
$1.2
+$0.02
(1.69%)
1D
Industry: Biotechnology Sector: Health Care

Actinium Pharmaceuticals Inc Analyst Forecast

Actinium Pharmaceuticals Inc Share Price Chart

Actinium Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$36.81M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
70.54K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.02 L
$2.41 H
$1.2

About Actinium Pharmaceuticals Inc, Common Stock

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York. more

Industry: BiotechnologySector: Health Care

Actinium Pharmaceuticals Inc Stock Returns

Time FrameATNMSectorS&P500
1-Week Return--3.93%-0.67%
1-Month Return2.61%-2.41%-1.33%
3-Month Return-15.71%1.64%-0.29%
6-Month Return-26.25%11.65%5.08%
1-Year Return3.51%3.11%19.01%
3-Year Return-88.43%19.21%68.62%
5-Year Return-85.03%36.52%78.6%
10-Year Return-98.05%126.5%240.69%

Actinium Pharmaceuticals Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue622.00K1.14M1.03M81.00K-[{"date":"2020-12-31","value":54.37,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.03,"profit":true},{"date":"2023-12-31","value":7.08,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue447.00K524.00K699.00K790.00K811.00K[{"date":"2020-12-31","value":55.12,"profit":true},{"date":"2021-12-31","value":64.61,"profit":true},{"date":"2022-12-31","value":86.19,"profit":true},{"date":"2023-12-31","value":97.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(447.00K)620.00K1.03M81.00K(811.00K)[{"date":"2020-12-31","value":-43.4,"profit":false},{"date":"2021-12-31","value":60.19,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.86,"profit":true},{"date":"2024-12-31","value":-78.74,"profit":false}]
Gross Margin(71.86%)54.20%100.00%100.00%-[{"date":"2020-12-31","value":-71.86,"profit":false},{"date":"2021-12-31","value":54.2,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses21.95M25.58M35.13M52.00M41.31M[{"date":"2020-12-31","value":42.2,"profit":true},{"date":"2021-12-31","value":49.2,"profit":true},{"date":"2022-12-31","value":67.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":79.44,"profit":true}]
Operating Income(22.39M)(24.96M)(34.10M)(51.92M)(42.12M)[{"date":"2020-12-31","value":-2239300000,"profit":false},{"date":"2021-12-31","value":-2496400000,"profit":false},{"date":"2022-12-31","value":-3410400000,"profit":false},{"date":"2023-12-31","value":-5192000000,"profit":false},{"date":"2024-12-31","value":-4212100000,"profit":false}]
Total Non-Operating Income/Expense356.00K380.00K2.17M5.83M7.76M[{"date":"2020-12-31","value":4.59,"profit":true},{"date":"2021-12-31","value":4.9,"profit":true},{"date":"2022-12-31","value":28.03,"profit":true},{"date":"2023-12-31","value":75.15,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(22.21M)(24.77M)(33.02M)(48.82M)(38.24M)[{"date":"2020-12-31","value":-2221500000,"profit":false},{"date":"2021-12-31","value":-2477400000,"profit":false},{"date":"2022-12-31","value":-3301700000,"profit":false},{"date":"2023-12-31","value":-4881800000,"profit":false},{"date":"2024-12-31","value":-3824300000,"profit":false}]
Income Taxes(178.00K)(190.00K)(1.09M)622.11K-[{"date":"2020-12-31","value":-28.61,"profit":false},{"date":"2021-12-31","value":-30.54,"profit":false},{"date":"2022-12-31","value":-174.73,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(22.04M)(24.58M)(31.93M)(49.44M)-[{"date":"2020-12-31","value":-2203700000,"profit":false},{"date":"2021-12-31","value":-2458400000,"profit":false},{"date":"2022-12-31","value":-3193000000,"profit":false},{"date":"2023-12-31","value":-4944010500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(22.21M)(24.77M)(33.02M)(50.14M)(38.24M)[{"date":"2020-12-31","value":-2221500000,"profit":false},{"date":"2021-12-31","value":-2477400000,"profit":false},{"date":"2022-12-31","value":-3301700000,"profit":false},{"date":"2023-12-31","value":-5014100000,"profit":false},{"date":"2024-12-31","value":-3824300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(22.21M)(24.77M)(33.02M)(48.82M)(38.24M)[{"date":"2020-12-31","value":-2221500000,"profit":false},{"date":"2021-12-31","value":-2477400000,"profit":false},{"date":"2022-12-31","value":-3301700000,"profit":false},{"date":"2023-12-31","value":-4881800000,"profit":false},{"date":"2024-12-31","value":-3824300000,"profit":false}]
EPS (Diluted)(2.04)(1.20)(1.37)(1.84)(1.27)[{"date":"2020-12-31","value":-204,"profit":false},{"date":"2021-12-31","value":-120,"profit":false},{"date":"2022-12-31","value":-137,"profit":false},{"date":"2023-12-31","value":-184,"profit":false},{"date":"2024-12-31","value":-127,"profit":false}]

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top